All In Biotech

Drug Trial Radar · NCT06863740

Using Cannabis to Treat Restless Legs Syndrome

Using Cannabis to Treat Restless Legs Syndrome: A Randomized Placebo Controlled Pilot Safety and Feasibility Trial

Last checked: Nov 20, 2026Latest source record: Apr 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

30

Planned (sponsor's estimate)

Start

Jul 25, 2025

Primary completion

Dec 2026

Study completion May 2027

Sponsor

Lead sponsor
Sunnybrook Health Sciences CentreAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
University Health Network, Toronto
First posted
Mar 7, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 25 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Restless Legs Syndrome (RLS) is a disorder that causes painful and uncomfortable sensations in the legs, and its symptoms have a significant impact on sleep and quality of life. Cannabis has been used by some RLS patients as a treatment due to its painkilling and drowsiness effects, however there has never been a clinical research trial investigating cannabis in patients with RLS. A controlled trial is needed to establish how safe and feasible cannabis is as a treatment for RLS. The investigators plan to randomize 30 participants with moderate-to-severe RLS to receive either cannabis or placebo for 8 weeks. The investigators will measure patients sleep quality and quality of life at baseline and 8-week follow-up. The investigators will also monitor patients for any adverse reactions to the study drug.

Conditions

  • Restless Leg Syndrome (RLS)

Interventions

  • Cannabis oilDrug

    5:1 CBD:THC oral formulation with a concentration of 25 mg/g CBD and 5 mg/g THC in a pharmaceutical grade medium chain triglyceride (MCT) oil.

  • Cannabis placeboDrug

    Placebo oil

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of Adverse Events and Serious Adverse EventsTime frame: 8 weeks
  2. Rate of Study CompletionTime frame: 8 weeks

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Sunnybrook Health Sciences Centre

    Toronto, Ontario, Canada · Recruiting

  • University Health Network

    Toronto, Ontario, Canada · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.